Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.79 |
| ▸ | CCR2 | P41597 | 14/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22461745 | 0.92 | CYP3A4 (0.67) | CYP3A4CCR2CYP2C9TSHRJAK1 | |
| SCHEMBL306637 | 0.92 | CYP2C9 (0.77) | CYP3A4CCR2CYP2C9TSHR | |
| SCHEMBL22461660 | 0.90 | CYP2C9 (0.65) | CYP3A4CCR2CYP2C9TSHRJAK1 | |
| SCHEMBL12594251 | 0.90 | CYP3A4 (0.63) | CYP3A4CCR2CYP2C9 | |
| SCHEMBL25023972 | 0.89 | CYP3A4 (0.64) | CYP3A4CCR2CYP2C9TSHRJAK1 | |
| SCHEMBL1762398 | 0.89 | CYP3A4 (0.63) | CYP3A4CCR2CYP2C9TSHRJAK1 | |
| SCHEMBL170192 | 0.89 | CYP3A4 (1.00) | CYP3A4CCR2CYP2C9TSHR | |
| SCHEMBL12594257 | 0.88 | CCR2 (0.79) | CYP3A4CCR2CYP2C9TSHRJAK1 | |
| Ilacirnon SCHEMBL127113 | 0.88 | CCR2 (1.00) | CYP3A4CCR2CYP2C9JAK1 | |
| Ilacirnon SCHEMBL31378455 | 0.88 | CCR2 (1.00) | CYP3A4CCR2CYP2C9JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | claimed |
| EP-3463350-B1 | PYRROLO-PYRIDINES AND PYRROLO-PYRIMIDINES FOR USE IN TREATING LIVER FIBROSIS | CHEMOCENTRYX INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-4134080-A1 | CCR2 INHIBITORS FOR USE IN TREATING RENAL DISEASES | ChemoCentryx, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11382915-B2 | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11357760-B2 | Method of treating liver fibrosis | CHEMOCENTRYX, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11324736-B2 | Method of Treating Focal Segmental Glomerulosclerosis | CHEMOCENTRYX, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP3A4 1934/4885CCR2 1/4885CYP2C9 192/4885 |
| US-11382915-B2 | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists | REN, CCR2, AGTR2 | CYP3A4 4759/4885CCR2 2/4885CYP2C9 4681/4885 |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP3A4 1934/4885CCR2 1/4885CYP2C9 192/4885 |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP3A4 1934/4885CCR2 1/4885CYP2C9 192/4885 |
| US-11324736-B2 | Method of Treating Focal Segmental Glomerulosclerosis | SLC5A1, PTGFR, HPGDS | CYP3A4 3325/4885CCR2 610/4885CYP2C9 2646/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | CYP3A4 3935/4885CCR2 1/4885CYP2C9 3501/4885 |
| US-11357760-B2 | Method of treating liver fibrosis | CCR2, CMKLR2, CCL2 | CYP3A4 1173/4885CCR2 1/4885CYP2C9 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.